Overview

* Lantheus ( LNTH ) Q2 revenue falls 4.1%, missing analyst expectations, per LSEG data

* Adjusted EPS for Q2 misses consensus, reflecting PSMA PET competition impact

* Co announces $400 mln stock repurchase program, expanding radiopharmaceutical portfolio

* Announced FDA acceptance of NDA for new formulation for piflufolastat F 18 PSMA PET imaging agent with a PDUFA date of March 6, 2026

Outlook

* Company sees FY 2025 revenue at $1.475 bln to $1.51 bln

* Lantheus ( LNTH ) expects FY 2025 adj EPS of $5.50 to $5.70

* Company cites increased PSMA PET competition impacting PYLARIFY performance

Result Drivers

* PSMA PET COMPETITION - Increased competition in the PSMA PET landscape impacted PYLARIFY sales, contributing to revenue decline

* ACQUISITIONS - Completed acquisitions of Evergreen Theragnostics and Life Molecular Imaging to expand radiopharmaceutical portfolio

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Miss $378 mln $389.10

Revenue mln (13

Analysts

)

Q2 Miss $1.57 $1.67

Adjusted (12

EPS Analysts

)

Q2 EPS $1.12

Q2 Free $79.10

Cash mln

Flow

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

* Wall Street's median 12-month price target for Lantheus Holdings Inc ( LNTH ) is $130.00, about 44.1% above its August 5 closing price of $72.63

* The stock recently traded at 10 times the next 12-month earnings vs. a P/E of 14 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)